118 related articles for article (PubMed ID: 9435868)
1. T cell activation and retargeting using staphylococcal enterotoxin B and bispecific antibody: an effective in vivo antitumor strategy.
Porter LE; Nelson H; Ethem Gecim I; Rice DC; Thibault C; Chapoval AI
Cancer Immunol Immunother; 1997; 45(3-4):180-3. PubMed ID: 9435868
[TBL] [Abstract][Full Text] [Related]
2. Induction of antitumor immunity after cure of pulmonary metastases, using staphylococcal enterotoxin B and bispecific antibody.
Rice DC; Chapoval AI; Porter L; Nelson H
Cancer Immunol Immunother; 1999 Aug; 48(5):230-8. PubMed ID: 10478639
[TBL] [Abstract][Full Text] [Related]
3. Depletion of activated Vbeta8+ T cells disrupts bispecific antibody directed antitumor immunity.
McConnell EJ; McLemore EC; Talac R; Joshi L; Nelson H
J Surg Res; 2004 Nov; 122(1):103-12. PubMed ID: 15522322
[TBL] [Abstract][Full Text] [Related]
4. Tumor-infiltrating lymphocytes can be activated in situ by using in vivo activants plus F(ab')2 bispecific antibodies.
Thibault C; Nelson H; Chapoval AI
Int J Cancer; 1996 Jul; 67(2):232-7. PubMed ID: 8760593
[TBL] [Abstract][Full Text] [Related]
5. The bispecific antibody 500A2 x 96.5 targets T-lymphocytes activated in vivo with staphylococcal enterotoxin B (SEB) against CL62 melanoma cells in vitro.
Reid IM; Lundy JK; Donohue JH
Surg Oncol; 1994 Oct; 3(5):279-85. PubMed ID: 7889221
[TBL] [Abstract][Full Text] [Related]
6. Bifunctional antibody retargeting in vivo-activated T lymphocytes: simplifying clinical application.
Chapoval AI; Nelson H; Thibault C; Penna C; Dean P
J Hematother; 1995 Dec; 4(6):571-7. PubMed ID: 8846018
[TBL] [Abstract][Full Text] [Related]
7. Antitumor x anti-CD3 bifunctional antibodies redirect T-cells activated in vivo with staphylococcal enterotoxin B to neutralize pulmonary metastases.
Penna C; Dean PA; Nelson H
Cancer Res; 1994 May; 54(10):2738-43. PubMed ID: 8168104
[TBL] [Abstract][Full Text] [Related]
8. Anti-CD3 x anti-tumor F(ab')2 bifunctional antibody activates and retargets tumor-infiltrating lymphocytes.
Chapoval AI; Nelson H; Thibault C
J Immunol; 1995 Aug; 155(3):1296-303. PubMed ID: 7636196
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of bispecific monoclonal antibody (bsAb)-targeted cytolysis by human anti-mouse antibodies in ovarian carcinoma patients treated with bsAb-targeted activated T-lymphocytes.
Lamers CH; Gratama JW; Warnaar SO; Stoter G; Bolhuis RL
Int J Cancer; 1995 Feb; 60(4):450-7. PubMed ID: 7829257
[TBL] [Abstract][Full Text] [Related]
10. Pulmonary metastases neutralization and tumor rejection by in vivo administration of beta glucan and bispecific antibody.
Penna C; Dean PA; Nelson H
Int J Cancer; 1996 Jan; 65(3):377-82. PubMed ID: 8575861
[TBL] [Abstract][Full Text] [Related]
11. Approaches to lung cancer treatment using the CD3 x EGP-2-directed bispecific monoclonal antibody BIS-1.
Kroesen BJ; Nieken J; Sleijfer DT; Molema G; de Vries EG; Groen HJ; Helfrich W; The TH; Mulder NH; de Leij L
Cancer Immunol Immunother; 1997; 45(3-4):203-6. PubMed ID: 9435874
[TBL] [Abstract][Full Text] [Related]
12. Tumor-growth inhibition with bispecific antibody fragments in a syngeneic mouse melanoma model: the role of targeted T-cell co-stimulation via CD28.
Grosse-Hovest L; Brandl M; Dohlsten M; Kalland T; Wilmanns W; Jung G
Int J Cancer; 1999 Jan; 80(1):138-44. PubMed ID: 9935244
[TBL] [Abstract][Full Text] [Related]
13. A T-cell-engaging B7-H4/CD3-bispecific Fab-scFv Antibody Targets Human Breast Cancer.
Iizuka A; Nonomura C; Ashizawa T; Kondou R; Ohshima K; Sugino T; Mitsuya K; Hayashi N; Nakasu Y; Maruyama K; Yamaguchi K; Akiyama Y
Clin Cancer Res; 2019 May; 25(9):2925-2934. PubMed ID: 30737243
[TBL] [Abstract][Full Text] [Related]
14. Costimulation of tumor-reactive CD4+ and CD8+ T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma.
Li Y; McGowan P; Hellström I; Hellström KE; Chen L
J Immunol; 1994 Jul; 153(1):421-8. PubMed ID: 7515929
[TBL] [Abstract][Full Text] [Related]
15. Anti-CD3-based bispecific antibody designed for therapy of human B-cell malignancy can induce T-cell activation by antigen-dependent and antigen-independent mechanisms.
Link BK; Kostelny SA; Cole MS; Fusselman WP; Tso JY; Weiner GJ
Int J Cancer; 1998 Jul; 77(2):251-6. PubMed ID: 9650561
[TBL] [Abstract][Full Text] [Related]
16. Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody.
Ruf P; Lindhofer H
Blood; 2001 Oct; 98(8):2526-34. PubMed ID: 11588051
[TBL] [Abstract][Full Text] [Related]
17. T cell activation and cytokine production in anti-CD3 bispecific antibody therapy.
Belani R; Weiner GJ
J Hematother; 1995 Oct; 4(5):395-402. PubMed ID: 8581375
[TBL] [Abstract][Full Text] [Related]
18. In vivo studies using bispecific antibodies (anti-CD3 x anti-idiotype) and CD28-induced costimulation in the BCL1 lymphoma.
Demanet C; Brissinck J; De Jonge J; Thielemans K
J Hematother; 1995 Oct; 4(5):363-8. PubMed ID: 8581370
[TBL] [Abstract][Full Text] [Related]
19. In vivo T-cell activation by staphylococcal enterotoxin B prevents outgrowth of a malignant tumor.
Newell KA; Ellenhorn JD; Bruce DS; Bluestone JA
Proc Natl Acad Sci U S A; 1991 Feb; 88(3):1074-8. PubMed ID: 1899481
[TBL] [Abstract][Full Text] [Related]
20. The role of T cell activation in anti-CD3 x antitumor bispecific antibody therapy.
Weiner GJ; Kostelny SA; Hillstrom JR; Cole MS; Link BK; Wang SL; Tso JY
J Immunol; 1994 Mar; 152(5):2385-92. PubMed ID: 8133049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
